Momenta’s biosimilars pullback could portend further industry exits
Expert says that biosimilars' pricing discounts and lower-than-expected patient populations could make the market less attractive for smaller players.
Expert says that biosimilars' pricing discounts and lower-than-expected patient populations could make the market less attractive for smaller players.